DRI Healthcare Trust (TSE:DHT.UN) PT Lowered to C$16.00

DRI Healthcare Trust (TSE:DHT.UN) had its price objective decreased by research analysts at Royal Bank of Canada from C$20.00 to C$16.00 in a research report issued to clients and investors on Tuesday, BayStreet.CA reports. Royal Bank of Canada’s target price points to a potential upside of 30.40% from the stock’s previous close.

Other equities research analysts have also issued research reports about the stock. National Bankshares reduced their price target on shares of DRI Healthcare Trust from C$23.50 to C$17.50 and set an “outperform” rating for the company in a report on Tuesday. Canaccord Genuity Group reduced their price target on shares of DRI Healthcare Trust from C$19.50 to C$19.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. CIBC boosted their price target on shares of DRI Healthcare Trust from C$19.50 to C$20.00 and gave the company an “outperform” rating in a report on Wednesday, May 8th. Finally, Raymond James lowered shares of DRI Healthcare Trust from a “strong-buy” rating to an “outperform” rating and set a C$24.00 price target for the company. in a report on Tuesday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of C$19.14.

DRI Healthcare Trust Price Performance

DRI Healthcare Trust stock opened at C$12.27 on Tuesday. DRI Healthcare Trust has a 1 year low of C$10.21 and a 1 year high of C$17.43. The firm has a 50-day moving average of C$15.03 and a two-hundred day moving average of C$14.92.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.